CCR5 and neoplasm: On one hand, CCR2/CCR5 antagonism is clearly preventing a tumor-associated increase of IM in the peripheral blood (Figure 5A), and since systemic numbers of IM are largely regulated by bone marrow output, it is possible that dual blockade of CCR2/CCR5 is preventing mobilization of IM from the bone marrow into the peripheral blood.